| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/09/2004 | CA2398828A1 A pharmaceutical composition containing an indolopyrrolocarbazole derivative |
| 02/06/2004 | CA2436890A1 Pharmaceutical preparation with rna as hemostasis cofactor |
| 02/05/2004 | WO2004011673A1 Auto-stimulating cells and method for making and using the same |
| 02/05/2004 | WO2004011628A1 New mutant strains of pseudomonas fluorescens and variants thereof, methods for their production, and uses thereof in alginate production |
| 02/05/2004 | WO2004011537A1 Porous beads and method of production thereof |
| 02/05/2004 | WO2004011054A2 Injectable multimodal polymer depot compositions and uses thereof |
| 02/05/2004 | WO2004011033A1 Method for the synthesis of anthracycline-peptide conjugates |
| 02/05/2004 | WO2004011032A1 External preparation |
| 02/05/2004 | WO2004011027A1 Chimeric multivalent polysaccharide conjugate vaccines |
| 02/05/2004 | WO2004011023A1 Pharmaceutically active substance preparations and drugs that are capable of generating thrombin and/or that contain thrombin |
| 02/05/2004 | WO2004011013A1 Psoriasis formulation and method of preparation |
| 02/05/2004 | WO2004011002A1 Sustained-release tablet composition comprising a dopamine receptor agonist |
| 02/05/2004 | WO2004011001A1 Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 02/05/2004 | WO2004011000A1 Parenteral formulations containing a rapamycin hydroxyester |
| 02/05/2004 | WO2004010998A1 Sustained-release tablet comprising reboxetine |
| 02/05/2004 | WO2004010997A1 Sustained-release tablet composition of pramipexole |
| 02/05/2004 | WO2004010994A1 Indometacin preparation for external use |
| 02/05/2004 | WO2004010993A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 02/05/2004 | WO2004010988A1 Percutaneous and perungual delivery system |
| 02/05/2004 | WO2004010984A2 Microcapsules with modified release of active principles with low solubility for oral delivery |
| 02/05/2004 | WO2004010982A1 Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
| 02/05/2004 | WO2004010980A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | WO2004010978A1 Multicomponent pharmaceutical dosage form |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010970A1 Formulations and dosage forms for controlled delivery of topiramate |
| 02/05/2004 | WO2004010969A1 Chinese herb medicine composition in the form of jelly |
| 02/05/2004 | WO2004010957A2 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 02/05/2004 | WO2004010941A2 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 02/05/2004 | WO2004010939A2 Methods of using non-human animal apoliprotein a-i protein |
| 02/05/2004 | WO2004010900A1 Devices delivering therapeutic agents and methods regarding the same |
| 02/05/2004 | WO2003099228A8 Compositions and processes for inhibiting gene expression using polynucleotides |
| 02/05/2004 | WO2003094828A3 Cancer vaccines and methods of using the same |
| 02/05/2004 | WO2003086293A3 Pharmaceutical preparation for taste masking |
| 02/05/2004 | WO2003082247A3 Drug microparticles |
| 02/05/2004 | WO2003082244A3 Hfa-suspension formulation of an anhydrate |
| 02/05/2004 | WO2003082195A9 Protamine-adenoviral vector complexes and methods of use |
| 02/05/2004 | WO2003080181A3 Storage stable eplerenone formulation |
| 02/05/2004 | WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 02/05/2004 | WO2003072735A3 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels |
| 02/05/2004 | WO2003072020A3 Therapeutical polyanhydride compounds for drug delivery |
| 02/05/2004 | WO2003070282A3 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue |
| 02/05/2004 | WO2003066067A3 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 02/05/2004 | WO2003016915A8 Tumor specific oligosaccharide sequences and use thereof |
| 02/05/2004 | WO2002072150A3 Micellar drug delivery vehicles and uses thereof |
| 02/05/2004 | US20040024725 Regulated apoptosis |
| 02/05/2004 | US20040024450 Drug-delivery endovascular stent and method for treating restenosis |
| 02/05/2004 | US20040024363 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/05/2004 | US20040024220 Lipids |
| 02/05/2004 | US20040024197 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 02/05/2004 | US20040024096 Dual stimuli-responsive hydrogels and their synthetic methods |
| 02/05/2004 | US20040024069 A biodegradable, biocompatible polymer, a water-immiscible solvent to plasticize the polymer and form a gel, a thixotropic agent and a beneficial agent; drug delivery; improved shear thinning and reduced injection |
| 02/05/2004 | US20040024044 In chemoprevention of estrogen dependent cancer in mammals, including humans |
| 02/05/2004 | US20040024036 May take form of gel, ointment or emulsion for local administration, of transdermal patch or of film deposited by a spray, characterized in that it comprises at least one absorption promoter |
| 02/05/2004 | US20040024025 Compositions and methods for inducing cell death |
| 02/05/2004 | US20040024018 Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| 02/05/2004 | US20040023902 Delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a |
| 02/05/2004 | US20040023899 Extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water |
| 02/05/2004 | US20040023892 Pharmaceutical composition based on a non-steroid anti-inflammatory agent |
| 02/05/2004 | US20040023862 Newly identified uses of BRS3 polypeptides and polynucleotides encoding such polypeptides, to their use in therapy of ischemia, of neurodegenerative diseases, of memory and attention disorders, and in identifying compounds which may be |
| 02/05/2004 | US20040023855 Biologic modulations with nanoparticles |
| 02/05/2004 | US20040023852 Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG |
| 02/05/2004 | US20040023847 (5-(2-Hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
| 02/05/2004 | US20040023842 Methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic groups capable of reacting and crosslinking in situ for seals |
| 02/05/2004 | US20040023334 Comprises lactoferrin fusion protein for diagnosis, prevention treatment and prognosis of nervous system, respiratory, cardiovascular and/or reproductive system disorders |
| 02/05/2004 | US20040023307 DNA encoding a novel RG1 polypeptide |
| 02/05/2004 | US20040023290 Novel therapeutic agents that modulate enzymatic processes |
| 02/05/2004 | US20040023204 Peptides which enhance transport across tissues and methods of identifying and using the same |
| 02/05/2004 | US20040022972 Consumable container |
| 02/05/2004 | US20040022879 Platelet Activating Factor Inhibitor and an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity; especially useful for treating asthma in children. |
| 02/05/2004 | US20040022868 Free of added persulfates. |
| 02/05/2004 | US20040022866 Use of sodium and potassium salts of citric, phosphoric, carbonic and tartaric acid and arginine and lysine as stabilizer of the antibiotic Fosfomycin Tromethamine |
| 02/05/2004 | US20040022864 Methods of delivering therapeutic agents |
| 02/05/2004 | US20040022860 Release composition and method of preparation |
| 02/05/2004 | US20040022859 Having a solvent with a miscibility in water of less than or equal to 7 wt. % at 25 degrees C., to plasticize the polymer and form a gel therewith; improved shear thinning behavior and reduced injection force |
| 02/05/2004 | US20040022854 Oral administration of proton pump inhibitor |
| 02/05/2004 | US20040022853 Polymer-based, sustained release drug delivery system |
| 02/05/2004 | US20040022852 Chemical delivery device |
| 02/05/2004 | US20040022851 Sustained release of guaifenesin combination drugs |
| 02/05/2004 | US20040022850 Modified release formulation |
| 02/05/2004 | US20040022849 Oral pharmaceutical composition with controlled release and prolonged absorption |
| 02/05/2004 | US20040022848 Does not cause adhesion of granules thereof onto a granulation apparatus during granulation and which prevents caking of the granules |
| 02/05/2004 | US20040022845 Oral formulations for localized colonic release and the method of preparation thereof |
| 02/05/2004 | US20040022842 Liposome preparations containing oxaliplatin |
| 02/05/2004 | US20040022837 Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
| 02/05/2004 | US20040022836 Transdermal therapeutic systems comprising photosensitive active substances |
| 02/05/2004 | US20040022835 Transdermal composition of an antivomiting agent |
| 02/05/2004 | US20040022831 For therapy of mycosis of the nail |
| 02/05/2004 | US20040022819 Surfactant, and an emulsion-type cosmetic composition and a liposome containing said surfactant |
| 02/05/2004 | US20040022815 Novel pharmaceutical composition of ceftiofur |
| 02/05/2004 | US20040022778 For therapy and prophylaxis of cardiovascular disease, strokes and myocardial infarction |
| 02/05/2004 | US20040022755 For coating substrates, such as tablets and capsules |
| 02/05/2004 | US20040022753 External application for enhancing the skin permeability of the active components therein |
| 02/05/2004 | US20040022739 Nasal spray formulation and method |
| 02/05/2004 | US20040022727 For therapy of proliferative diseases |
| 02/05/2004 | US20040022726 Administering via urethra multispecific antibody; allowing antibody to localize at the site of bladder cancer, allowing free antibody to clear from patient; administering carrier conjugated to one or more therapeutic agents |
| 02/05/2004 | DE10230917A1 Fredericamycin-Derivate Fredericamycin derivatives |
| 02/05/2004 | CA2802205A1 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 02/05/2004 | CA2494400A1 Injectable multimodal polymer depot compositions and uses thereof |